India Markets closed

Knight Therapeutics Inc. announces voting results from the Annual Meeting

MONTREAL, June 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (GUD.TO) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec ("Meeting").

Election of Directors

Each director nominee listed in the Management Information Circular dated May 26, 2020 ("Circular") was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows:

DIRECTOR NOMINEE

OUTCOME

VOTES FOR

% FOR

VOTES WITHHELD

%
WITHHELD

James C. Gale

Elected

84,542,688

94.19%

5,218,368

5.81%

Jonathan Ross Goodman

Elected

89,596,616

99.82%

164,440

0.18%

Samira Sakhia

Elected

87,295,361

97.25%

2,465,695

2.75%

Robert N. Lande

Elected

86,384,815

96.24%

3,376,241

3.76%

Michael J Tremblay

Elected

89,577,845

99.80%

183,211

0.20%

Nicolas Sujoy

Elected

89,602,776

99.82%

158,280

0.18%

Janice Murray

Elected

89,603,776

99.82%

157,280

0.18%

Appointment of external Auditors

Ernst & Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present or represented by proxy, and the directors were authorized to determine their remuneration. Shareholders present in person or represented by proxy at the Meeting voted as follows:

OUTCOME

VOTES FOR

% FOR

VOTES WITHHELD

% WITHHELD

Appointed

90,281,521

99.74%

232,255

0.26%

The results of the final votes regarding all matters subject to a vote during the Meeting will also be made available on SEDAR (www.sedar.com).

Approval of Unallocated Options under the Corporation’s Stock Option Plan

The resolution to approve unallocated rights under the Corporation's stock option plan for the ensuing three years, as described in the Circular, was approved by a majority of the votes cast by the shareholders present or represented by proxy. Shareholders present in person or represented by proxy at the Meeting voted as follows:

OUTCOME

VOTES FOR

% FOR

VOTES AGAINST

% AGAINST

Approved

77,755,731

86.63%

12,005,325

13.37%

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a panLatin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2019. filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

CONTACT INFORMATION:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia
President
T: 514-678-8930
F: 514-481-4116
Email: info@gudknight.com
Website: www.gud-knight.com

Knight Therapeutics Inc.
Arvind Utchanah
Chief Financial Officer
T. 514.484.4483 ext. 115
F. 514.481.4116
Email: info@gudknight.com
Website: www.gud-knight.com